2 news items
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
ELTX
10 Jun 24
science, immunology and oncology, it plans to forge a new path forward for cancer treatment by utilizing its diverse capabilities to fulfill its mission
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
23 May 24
to the number of diverse mutations and bypass resistance mechanisms. We are encouraged by the first data from the ongoing AMPLIFY-7P trial, which
- Prev
- 1
- Next